Harmony Biosciences Holdings, Inc. (HRMY) stock
HRMYNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 18/3039% below fair value
$33.11+0.10 (+0.30%)
Close on Nov 18, 2026Market cap $1.93BP/E 10.7Yield –
Harmony Biosciences r&d expenses
Research and development expenses are spending on new products and technology.
Harmony Biosciences's R&D Expenses for the twelve months ending Jun 30, 2026 was $220.87M, up 52.6% year over year. For fiscal 2025 it was $189.59M, up 30.0% from the year before. The highest annual figure on record is $189.59M in fiscal 2025.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $189.59M | +30.0% |
| FY2024 | Dec 31, 2024 | $145.83M | +91.7% |
| FY2023 | Dec 31, 2023 | $76.06M | +7.3% |
| FY2022 | Dec 31, 2022 | $70.89M | +133.4% |
| FY2021 | Dec 31, 2021 | $30.37M | +56.1% |
| FY2020 | Dec 31, 2020 | $19.45M | -72.1% |
| FY2019 | Dec 31, 2019 | $69.60M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $46.60M | -7.1% |
| Q1 FY2026 | Mar 31, 2026 | $69.38M | +100.9% |
| Q4 FY2025 | Dec 31, 2025 | $49.93M | +44.0% |
| Q3 FY2025 | Sep 30, 2025 | $54.96M | +116.5% |
| Q2 FY2025 | Jun 30, 2025 | $50.16M | -21.1% |
| Q1 FY2025 | Mar 31, 2025 | $34.54M | +55.7% |
| Q4 FY2024 | Dec 31, 2024 | $34.67M | +14.4% |
| Q3 FY2024 | Sep 30, 2024 | $25.39M | +45.1% |
| Q2 FY2024 | Jun 30, 2024 | $63.58M | +324.8% |
| Q1 FY2024 | Mar 31, 2024 | $22.19M | +67.0% |
| Q4 FY2023 | Dec 31, 2023 | $30.31M | +200.3% |
| Q3 FY2023 | Sep 30, 2023 | $17.50M | -56.8% |
| Q2 FY2023 | Jun 30, 2023 | $14.97M | +18.2% |
| Q1 FY2023 | Mar 31, 2023 | $13.29M | +75.4% |
| Q4 FY2022 | Dec 31, 2022 | $10.09M | +35.4% |
| Q3 FY2022 | Sep 30, 2022 | $40.55M | +245.4% |
| Q2 FY2022 | Jun 30, 2022 | $12.67M | +95.0% |
| Q1 FY2022 | Mar 31, 2022 | $7.58M | +62.0% |
| Q4 FY2021 | Dec 31, 2021 | $7.45M | -2.2% |
| Q3 FY2021 | Sep 30, 2021 | $11.74M | +177.5% |
| Q2 FY2021 | Jun 30, 2021 | $6.50M | +55.9% |
| Q1 FY2021 | Mar 31, 2021 | $4.68M | +36.4% |
| Q4 FY2020 | Dec 31, 2020 | $7.62M | +4.7% |
| Q3 FY2020 | Sep 30, 2020 | $4.23M | -2.4% |
| Q2 FY2020 | Jun 30, 2020 | $4.17M | – |
| Q1 FY2020 | Mar 31, 2020 | $3.43M | – |
| Q4 FY2019 | Dec 31, 2019 | $7.28M | – |
| Q3 FY2019 | Sep 30, 2019 | $4.34M | – |
See a number that looks wrong?